TP53 and small cell lung carcinoma: First, the safety of the Ad.p53-DC vaccine was confirmed and second, the vaccine was able to elicit a specific cytotoxic T cell response in 20-40% of the patients with extensive SCLC, possibly influenced by the co-administration of ATRA.